Biotech · Private company
Sarfez Pharmaceuticals, Inc.
Track this companyFree. Adds Sarfez Pharmaceuticals, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials80 recruiting or active
Pipeline programs16From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline16
- 10 mg Torsemide tabletPhase 3 · Bioequivalence Study in Healthy SubjectsClinicalTrials.gov · fetched Nov 12, 2026
- 25 mg Aldactone (Spironolactone) tabletPhase 3 · Bioequivalence Study in Healthy SubjectsClinicalTrials.gov · fetched Nov 12, 2026
- Combination Product: FDC of spironolactone and ER torsemidePhase 3 · Hypertension (HTN)ClinicalTrials.gov · fetched Nov 12, 2026
- Combination Product: Stabilized doses of loop diuretic and finerenonePhase 3 · Hypertension (HTN)ClinicalTrials.gov · fetched Nov 12, 2026
- FDC (12 mg ER Torsemide + 15mg Spironolactone) tabletPhase 3 · Bioequivalence Study in Healthy SubjectsClinicalTrials.gov · fetched Nov 12, 2026
- FDC (24 mg ER torsemide and 30 mg Spironolactone) with foodPhase 3 · Bioavailability Heathy VolunteersClinicalTrials.gov · fetched Nov 12, 2026
- FDC (24 mg ER torsemide and 30 mg Spironolactone) without foodPhase 3 · Bioavailability Heathy VolunteersClinicalTrials.gov · fetched Nov 12, 2026
- Torsemide and Spironolactone tabletPhase 3 · Bioavailability Heathy VolunteersClinicalTrials.gov · fetched Nov 12, 2026
- Torsemide Tablets and Spironolactone TabletsPhase 3 · Bioavailability Heathy VolunteersClinicalTrials.gov · fetched Nov 12, 2026
- Extended release torsemidePhase 2 · Heart FailureClinicalTrials.gov · fetched Nov 12, 2026
- Extended release torsemide 24mg tabletPhase 2 · Heart FailureClinicalTrials.gov · fetched Nov 12, 2026
- Immediate release torsemidePhase 2 · Heart FailureClinicalTrials.gov · fetched Nov 12, 2026
- Immediate release torsemide 20mg tabletPhase 2 · Heart FailureClinicalTrials.gov · fetched Nov 12, 2026
- Extended Release Torsemide TabletsHeart FailureClinicalTrials.gov · fetched Nov 12, 2026
- Immedate Release Torsemide TabletsHeart FailureClinicalTrials.gov · fetched Nov 12, 2026
- torsemideHeart FailureClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials8
- Bioavailability and Bioequivalence Study of ER Torsemide and Spironolactone FDC Tablet in Healthy SubjectsPHASE3 · COMPLETED · started Jul 1, 2025ClinicalTrials.gov NCT07015671 · fetched Nov 12, 2026
- Bioavailability and Bioequivalence Study of Extended Release Torsemide and SpironolactonePHASE3 · COMPLETED · started Jun 15, 2025ClinicalTrials.gov NCT07046975 · fetched Nov 12, 2026
- A Study to Evaluate the Effect of Food or no Food on the Bioavailability of an Extended Release (ER) Torsemide and Spironolactone Fixed Dose Combination (FDC) Tablet in Healthy Adult SubjectsPHASE3 · COMPLETED · started Jun 15, 2025ClinicalTrials.gov NCT07043634 · fetched Nov 12, 2026
- Comparing Natriuretic Effects of ER Torsemide to IR Torsemide in Patients With Heart FailurePHASE4 · WITHDRAWN · started May 1, 2025ClinicalTrials.gov NCT06995144 · fetched Nov 12, 2026
- A Study Comparing the Clinical Benefit of Finerenone Versus a Fixed Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients With Hypertension and Chronic Kidney DiseasePHASE3 · WITHDRAWN · started May 1, 2025ClinicalTrials.gov NCT07223502 · fetched Nov 12, 2026
- A Crossover Study of Patients With HF to Compare Natriuretic Effects of IR Torsemide vs. ER Torsemide Over 12 HrsPHASE4 · WITHDRAWN · started Jan 15, 2025ClinicalTrials.gov NCT06708611 · fetched Nov 12, 2026
- Immediate Release Torsemide Versus Extended Release Torsemide After Salty MealPHASE2 · WITHDRAWN · started Nov 15, 2024ClinicalTrials.gov NCT06176794 · fetched Nov 12, 2026
- Effect of Extended Release Torsemide in Patients With Congestive Heart Failure and Overactive BladderPHASE2 · COMPLETED · started Jun 15, 2024ClinicalTrials.gov NCT06206512 · fetched Nov 12, 2026